Alzheimer’s Disease: Epidemiology Forecast to 2028

Alzheimers Disease: Epidemiology Forecast to 2028



Alzheimers Disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly. AD is characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities including thinking, language, and learning capacity (National Institute on Aging, 2019). AD is the most common type of dementia (Centers for Disease Control and Prevention, 2019).

It epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for AD was based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV) and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) criteria. The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of AD in the 8MM, segmented by age, sex, and severity.

The following data describes epidemiology of AD. In the 8MM, It epidemiologists forecast an increase in the total prevalent cases of AD from 32,753,241 cases in 2018 to 44,473,527 cases in 2028 at an AGR of 3.58% during the forecast period. In the 8MM, the diagnosed prevalent cases of AD will increase from 9,120,848 cases in 2018 to 12,348,971 cases in 2028 at an AGR of 3.54% during the forecast period. AD is more common in older adults. These trends are reflected in forecast for the total prevalent cases, and diagnosed prevalent cases for the 8MM.

Scope

- The Alzheimers disease (AD) Epidemiology Report provides an overview of the risk factors and global trends of AD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
- The report includes a 10-year epidemiological forecast for the prevalent cases of AD (total and diagnosed) segmented by sex, age (ages 60 years), and severity in these markets. Additionally, this report provides a 10-year epidemiological forecast for the prevalent cases of mild cognitive impairment (MCI) (total and diagnosed) segmented by sex and age (ages 60 years) in these markets.
- The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The Alzheimers Disease Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global AD market.
- Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
- Understand magnitude of AD population by severity at diagnosis.

2 Alzheimers Disease: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for AD (2018-2028)
3.5.1 Total Prevalent Cases of AD
3.5.2 Sex-Specific Total Prevalent Cases of AD
3.5.3 Age-Specific Total Prevalent Cases of AD
3.5.4 Total Prevalent Cases of AD by Severity
3.5.5 Diagnosed Prevalent Cases of AD
3.5.6 Sex-Specific Diagnosed Prevalent Cases of AD
3.5.7 Age-Specific Diagnosed Prevalent Cases of AD
3.5.8 Diagnosed Prevalent Cases of AD by Severity
3.5.9 Total Prevalent Cases of Mild Cognitive Impairment
3.5.10 Sex-Specific Total Prevalent Cases of Mild Cognitive Impairment
3.5.11 Age-Specific Total Prevalent Cases of Mild Cognitive Impairment
3.5.12 Diagnosed Prevalent Cases of Mild Cognitive Impairment
3.5.13 Sex-Specific Diagnosed Prevalent Cases of Mild Cognitive Impairment
3.5.14 Age-Specific Diagnosed Prevalent Cases of Mild Cognitive Impairment
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - KOLs Interviewed for this Report
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer

List Of Tables

Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for AD

List Of Figures

Figure 1: 8MM, Total Prevalent Cases of AD, Men and Women, Ages 60 Years, 2018 and 2028
Figure 2: 8MM, Diagnosed Prevalent Cases of AD, Men and Women, Ages 60 Years, 2018 and 2028
Figure 3: 8MM, Total Prevalence of AD (%), Men and Women, Ages 60 Years, 2018
Figure 4: 8MM, Total Prevalence of MCI, Men and Women, Ages 60 Years, 2018
Figure 5: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of AD Based on the DSM-IV and Clinical Criteria
Figure 6: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of MCI
Figure 7: 8MM, Sources Used to Forecast the Total Prevalent Cases of AD by Severity
Figure 8: 8MM, Total Prevalent Cases of AD, Both Sexes, Ages 60 Years
Figure 9: 8MM, Total Prevalent Cases of AD, by Sex, Ages 60 Years, N, 2018
Figure 10: 8MM, Total Prevalent Cases of AD by Age, Both Sexes, N, 2018
Figure 11: 8MM, Total Prevalent Cases of AD by Severity, Both Sexes, Ages 60 Years, N, 2018
Figure 12: 8MM, Diagnosed Prevalent Cases of AD, Both Sexes, Ages 60 Years, N, 2018
Figure 13: 8MM, Diagnosed Prevalent Cases of AD, by Sex, Ages 60 Years, N, 2018
Figure 14: 8MM, Diagnosed Prevalent Cases of AD by Age, Both Sexes, N, 2018
Figure 15: 8MM, Diagnosed Prevalent Cases of AD by Severity, Both Sexes, Ages 60 Years, N, 2018
Figure 16: 8MM, Total Prevalent Cases of MCI, Both Sexes, Ages 60 Years
Figure 17: 8MM, Total Prevalent Cases of MCI, by Sex, Ages 60 Years, N, 2018
Figure 18: 8MM, Total Prevalent Cases of MCI by Age, Both Sexes, N, 2018
Figure 19: 8MM, Diagnosed Prevalent Cases of MCI, Both Sexes, Ages 60 Years
Figure 20: 8MM, Diagnosed Prevalent Cases of MCI, by Sex, Ages 60 Years, N, 2018
Figure 21: 8MM, Diagnosed Prevalent Cases of MCI by Age, Both Sexes, N, 2018

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available